Kyorin Pharmaceutical Co.,ltd.TSE: 4569

KYORIN Pharmaceutical: Strong nine-month results, but full-year outlook projects lower sales and profits

· Issued by Kyorin Pharmaceutical Co.,ltd.

Net sales and profits rose significantly year-over-year for the nine months ended December 31, 2025, but full-year forecasts anticipate declines in sales and earnings. Equity ratio improved, and the dividend forecast remains unchanged at ¥57.00 per share.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Kyorin Pharmaceutical Co.,ltd

All Kyorin Pharmaceutical Co.,ltd news releases